Clik here to view.
Adalvo Acquires Its First Branded Product, Onsolis®
MSIDA, Malta The global pharmaceutical company Adalvo today announced the acquisition of its first branded product, Onsolis® after concluding a deal with a reputable US based specialty...
View ArticleClik here to view.
Adalvo收购其首个品牌产品Onsolis®
马耳他姆西达 (美国商业资讯)–全球制药公司Adalvo今天宣布，该公司与一家声誉良好的美国专业制药公司达成交易，收购了其首个品牌产品Onsolis®。这家美国制药公司是该产品的原始拥有者。...
View ArticleClik here to view.
アダルボが初のブランド製品オンソリスを取得
マルタ・ムサイダ （ビジネスワイヤ） — 世界的製薬企業のアダルボは本日、当社初のブランド製品であるオンソリスを、その最初の保有者で、米国を拠点とするスペシャルティ製薬会社として評判の高い企業との契約締結により取得したと発表しました。...
View ArticleClik here to view.
Tongji Hospital Begins Installation of Mevion Proton Therapy System
LITTLETON, Mass. Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced today that the accelerator for the...
View ArticleClik here to view.
World’s First Discovery of Scallop-derived Plasmalogens Enhancing Antiviral...
FUKUOKA, Japan The Japanese Plasmalogen Society (Office: Higashi-ku, Fukuoka, Japan; President: Yutaka Oomura) announced the research results that scallop-derived plasmalogens enhanced antiviral...
View ArticleClik here to view.
GenomOncology和Congenica宣布合作开发新型精准肿瘤学解决方案
英格兰剑桥 (美国商业资讯)–Congenica是一家总部位于英国的数字健康公司，致力于实现基因组数据的快速分析与解读。该公司已选择GenomOncology的精准肿瘤学平台来开发一种新颖的突破性CE-IVD精准肿瘤学解决方案。 本新闻稿包含多媒体。此处查看新闻稿全文： https://www.businesswire.com/news/home/20220803005524/zh-CN/...
View ArticleClik here to view.
ゲノムオンコロジーとコンジェニカが新規精密オンコロジーソリューションの共同開発を発表
英ケンブリッジ （ビジネスワイヤ） — ゲノムデータの迅速な解析と解釈を実現する英国のデジタルヘルス企業であるコンジェニカは、画期的な新規CE-IVD精密オンコロジーソリューションの開発にゲノムオンコロジーの精密オンコロジープラットフォームを採用しました。...
View ArticleClik here to view.
Review of SURPASS-ET Trial Evaluating Ropeginterferon Alfa-2b-njft for...
BURLINGTON, Mass. PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven...
View ArticleClik here to view.
HERTHENA-Lung02 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo (TSE: 4568) announced today that the first patient has been dosed in the global HERTHENA-Lung02 phase 3 trial evaluating the efficacy and safety of...
View ArticleClik here to view.
Datopotamab Deruxtecan-Based Combinations Show Promising Clinical Activity in...
TOKYO & BASKING RIDGE, N.J. Initial results from the TROPION-Lung02 phase 1b trial showed that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum...
View ArticleClik here to view.
Cellworks Singula™ TRI Provides Superior OS Predictions for NSCLC Patients...
SOUTH SAN FRANCISCO, Calif. Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-203A...
View ArticleClik here to view.
Cullgen Announces Chinese NMPA Allowance of Investigational New Drug...
SAN DIEGO Cullgen Inc., a leading biotechnology company developing targeted protein degraders based on its proprietary uSMITE™ platform technology, today announced that the Chinese National Medical...
View ArticleClik here to view.
Clik here to view.
Clik here to view.
ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult...
View ArticleClik here to view.
InnoCare Announces Acceptance of Supplemental New Drug Application for...
BEIJING InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China...
View ArticleClik here to view.
Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen
TOKYO & MUNICH & BASKING RIDGE, N.J. An arbitrator issued a decision today in a dispute between Daiichi Sankyo Company, Ltd. and Seagen, Inc., denying all claims made by Seagen....
View ArticleClik here to view.
ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase...
TOKYO & MUNICH & BASKING RIDGE, N.J. Positive topline results from the DESTINY-Breast02 phase 3 trial of ENHERTU® (trastuzumab deruxtecan) versus physician’s choice of treatment showed the...
View ArticleClik here to view.
BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company that is developing and commercializing innovative and...
View ArticleClik here to view.
EpiAxis Therapeutics ＆ Peptilogics Enter Strategic Drug Discovery Partnership
SYDNEY & PITTSBURGH EpiAxis Therapeutics, a leading epigenetics company with a focus on the treatment, diagnosis and monitoring of cancer and the prevention of its recurrence, and Peptilogics, a...
View Article